A look at current and potential treatment approaches for hormone receptor‐positive, HER2‐negative early breast cancer. (10th May 2022)

• Record Type: Journal Article
• Authors: Harbeck, Nadia; Burstein, Harold J.; Hurvitz, Sara A.; Johnston, Stephen; Vidal, Gregory A.
• Is Part Of: Cancer. Volume 128:Supplement S11(2022)
• Page Start: 2209
• Page End: 2223
• Publication Date: 2022-05-10
• Subjects: adjuvant therapy -- breast cancer -- chemotherapy -- cyclin‐dependent kinase (CDK) -- endocrine therapy -- risk factors; Cancer -- Periodicals; Cancer -- Cytopathology -- Periodicals; 616.99405
• DOI: 10.1002/cncr.34161
• Languages: English
• ISSNs: 0008-543X

Abstract

Abstract : The heterogeneity of hormone receptor (HR)‐positive, HER2‐negative early breast cancers reinforces the importance of individualized, risk‐adapted treatment approaches. Numerous factors contribute to the risk for recurrence, including clinical tumor features, individual biomarkers, and genomic risk. Current standard approaches for patients with HR‐positive, HER2‐negative, early stage disease focus on endocrine therapy and chemotherapy. The specific treatment regimen and duration of adjuvant therapy should be selected based on accurate risk assessment, tolerability of available therapies, and consideration for patient preferences. For patients with high‐risk features, such as highly proliferative tumors, large tumor size, and significant nodal involvement, the risk for recurrence remains clinically significant despite appropriate adjuvant treatment with current standards of care. This has driven investigation into novel treatment approaches, including the addition of cyclin‐dependent kinase 4 and 6 inhibitors to adjuvant endocrine therapy. Cyclin‐dependent kinase 4 and 6 inhibition has demonstrated significant efficacy in patients with high‐risk, HR‐positive, HER2‐negative, nonmetastatic breast cancer and now offers a new strategy to greatly improve outcomes in this difficult to treat patient population.; LAY SUMMARY: Hormone receptor (HR)‐positive, HER2‐negative early breast cancers are highly diverse and need to be managed differently for individual patients. The use of adjuvant endocrine therapy and chemotherapy should be driven by a patient's risk for recurrence, preferences, and risk for side effects. Patients with high‐risk tumors have a persistently elevated risk for recurrence despite current standards of care. Emerging cyclin‐dependent kinase 4 and 6 inhibitors are highly effective when added to endocrine therapy in high‐risk, HR‐positive early breast cancer and have the potential to improve patient outcomes in this difficult to treat patient population. Abstract : Treatment of hormone receptor‐positive, HER2‐negative early breast cancer should be individualized based on a patient's risk for recurrence. Optimal selection of endocrine therapy, chemotherapy, and emerging targeted agents is driven by risk assessment, tolerability, and consideration for patient preferences.